Repository logo
 
Publication

Is there a link between NRF2 and depression?

dc.contributor.authorSantos, Marlene
dc.contributor.authorFonseca, Débora
dc.contributor.authorCaldevilla, Renato
dc.contributor.authorBarroso, M. Fátima
dc.contributor.authorCruz, Agostinho
dc.date.accessioned2023-09-14T15:25:29Z
dc.date.available2023-09-14T15:25:29Z
dc.date.issued2023-04
dc.description.abstractDepression is a common mental health disorder that affects millions of people worldwide. Recent studies have highlighted the role of oxidative stress and inflammation in the pathogenesis of depression. NRF2 is a transcription factor that plays a crucial role in cellular defense against oxidative stress by binding to antioxidant response elements (AREs) located in the promoter region of various phase II antioxidant enzymes and stress-responsive enzymes. Decreased Keap1-Nrf2 signaling has been implicated in the development of mood disorders, such as Major Depressive Disorder. Therefore, this review aims to evaluate the in vitro and in vivo evidence of the involvement of Nrf2 in depression. A review was conducted on the PubMed database for articles published until March 8, 2022 Papers that evaluated NRF2 in animals and/or cell lines with depression and were published in English were included in the review. Studies that addressed other diseases/topics, systematic reviews, and those that did not address NRF2 were excluded. Quality assessment was performed according to Koch et al., 2022. Out of the 203 possibly relevant abstracts found through the PubMed search, 45 papers were included in the review. The results suggest that Nrf2 levels tend to decrease in animals exposed to oxidative stress or depressive behavior. When animals were treated with antidepressants or anti-inflammatory drugs, Nrf2 levels increased. Additionally, the study found that IL-10 and BDNF were key elements that were positively influenced by Nrf2 levels, protecting against oxidative stress through Keap1/Nrf2. The findings suggest that Nrf2 activation may play a crucial role in controlling oxidative stress and inflammation during depression. Furthermore, it provides evidence of the involvement of Nrf2 in depression and highlights its potential as a therapeutic target. However, further studies on clinical samples are necessary to evaluate NRF2’s putative effect in depression and antidepressant response.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationSantos, M., Fonseca, D., Caldevilla, R., Barroso, M. F., & Cruz, A. (2023). Is there a link between NRF2 and depression? 4th BenBedPhar Scientific meeting «From Physiology to Pathology», 12.
dc.identifier.urihttp://hdl.handle.net/10400.22/23535
dc.language.isoengpt_PT
dc.publisherCOSTpt_PT
dc.relation.publisherversionhttps://benbedphar.org/wp-content/uploads/2023/04/Abstract-book-BenBedPhar-Zagreb.pdfpt_PT
dc.titleIs there a link between NRF2 and depression?pt_PT
dc.typeconference object
dspace.entity.typePublication
oaire.citation.conferencePlaceCroáciapt_PT
oaire.citation.startPage12pt_PT
oaire.citation.title4th BenBedPhar Meeting From Physiology to Pathologypt_PT
person.familyNameSantos
person.familyNameManuel de Caldevilla Carvalho
person.givenNameMarlene
person.givenNameRenato
person.identifier1508370
person.identifier2868531
person.identifier.ciencia-id8311-B967-31C4
person.identifier.ciencia-id4817-5B7F-4D35
person.identifier.orcid0000-0001-5020-5942
person.identifier.orcid0009-0009-5272-4178
person.identifier.scopus-author-id57110502000
rcaap.rightsopenAccesspt_PT
rcaap.typeconferenceObjectpt_PT
relation.isAuthorOfPublication8ce9ee39-a4c6-46ae-99e2-49397b550f1b
relation.isAuthorOfPublicationfa11c04f-84f8-4db3-8a2d-8e9fe13fe991
relation.isAuthorOfPublication.latestForDiscoveryfa11c04f-84f8-4db3-8a2d-8e9fe13fe991

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
COM_Marlene Santos.pdf
Size:
141.64 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: